Gordian Pharma

Gordian Biotechnology is a drug discovery company focused on developing therapies for complex diseases of aging. The company utilizes a proprietary in vivo screening platform that allows for the simultaneous testing of hundreds of therapeutic candidates in individual animals, bypassing the limitations of traditional cell culture and animal models. By measuring the efficacy of gene therapies directly in the complex environment of a living organ, Gordian aims to significantly increase the success rate of clinical trials. Their current internal pipeline targets high-unmet-need areas including nonalcoholic steatohepatitis (NASH), heart failure, and osteoarthritis.